− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared to Placebo at Week 121
− Based on the Positive Results, Takeda Intends to Initiate a Phase 3 Study of TAK-279 in Psoriatic Arthritis
− Full Clinical Results Will be Presented at an Upcoming Medical Meeting
(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis. The study met its primary endpoint with a greater proportion of patients treated once-daily with TAK-279 achieving at least a 20 percent improvement in signs and symptoms of disease (American College of Rheumatology 20 response) at week 12 comp
...
Read more »
|
HAMILTON, Bermuda - Monday, 11. September 2023
Bacardi to accelerate brand growth within fast-growing super premium mezcal category
(BUSINESS WIRE) -- Bacardi Limited, the largest privately held international spirits company in the world, announced today the completion of a transaction that makes the family-owned company the sole owner of ILEGAL Mezcal®, a leading super premium artisanal mezcal.
The transaction follows a successful relationship in which Bacardi partnered with ILEGAL since 2015.
The super premium plus mezcal category is growing at a fast pace and is expected to grow at a CAGR of 16% over the next five years according to IWSR. Between now and 2027, the agave category – which includes both mezcal and tequila – is expected to be the sixth largest category globally, and it recently overtook American Whiskey to become the second largest category (by value) in the U.S. At 86% of global market share, the United States dominate
...
Read more »
|
NEWTON, Mass. & PETACH TIKVA, Israel
(BUSINESS WIRE)--CyberArk (NASDAQ: CYBR), the identity security company, today announced it has been named a Leader in the 2023 Gartner® Magic Quadrant™ for Privileged Access Management.1 CyberArk is recognized in this report for the fifth consecutive time. Additionally, CyberArk is the only vendor positioned as a Leader in both Gartner Magic Quadrant Privileged Access Management (PAM) and Access Management2 reports.
The CyberArk Identity Security Platform enables organizations to secure all identities – including workforce, IT, developer and non-human – against cyber threats with intelligent privilege controls. With CyberArk, customers have a single, unified platform for identity security that delivers operational efficiencies and faster ROI. Core to the platform are PAM solutions that secure standing, just-in-time and zero standing privileged access across hybrid and multi-cloud environments, and th
...
Read more »
|
QF’s Stars of Science milestone season 15 highlights the long-term benefits of strengthening the culture of innovation in the Middle East
Almost 60% of the Arab world’s population is made up of people under 25 years of age, making it the most youthful region globally. The potential, capabilities and promise that this demography holds for scientific innovation are being explored through another new season of Stars of Science, whose studios in Qatar Science & Technology Park came alive as the first round of auditions kickstarted its milestone season 15.
A platform for showcasing regional talent and innovation, Qatar Foundation’s (QF) long-standing edutainment show will see Stars of Science participants develop their solutions with the support of mentor
...
Read more »
|
SINOVAC Reports on the Clinical Trial Progress
Clinical trials will advance treatment of COVID-19 infection.
(BUSINESS WIRE) -- Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection (“SA55 Injection”) in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.
SINOVAC’s SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24, 2023. The phase I clinical trial has confirmed its preliminary safety profile in 40 healthy adults aged 18 to 65 in China.
The phase II clinical trial is a multicenter, randomized, double-blind, placebo-controlled study. I
...
Read more »
| |